ABSTRACT
Chlorinated paraffins (CPs) disrupt mitochondrial regulation of redox homeostasis, generating excessive reactive oxygen species. The resulting oxidative stress disturbs gut microbiota‐liver crosstalk and ultimately induces lipid metabolic disorders, yet effective strategies to restore this metabolic communication remain limited. Inspired by the natural mitochondrial Mn‐superoxide dismutase (Mn‐SOD) and the biocompatibility of manganese, we constructed an octahedral MIL‐100(Mn) nanozyme. Structurally, the unique µ 3‐oxo‐bridged trinuclear clusters within MIL‐100 topology simulate the active center of natural Mn‐SOD, offering more accessible metal active sites and hierarchical pores that enhance the adsorption of reaction intermediates and stabilize the thermodynamic environment, thereby improving catalytic efficiency compared with disordered Mn‐BTC. Functionally, administration of MIL‐100(Mn) enhanced the total SOD activity ∼8.75‐fold, while the cascade of CAT activity prevented the potential toxic accumulation of H2O2. Following oral administration, MIL‐100(Mn) reversed CP‐induced lipid metabolic abnormalities in mice. Multi‐omics integration revealed that this metabolic rescue is highly correlated with the coordinated reprogramming of the gut‐liver axis, characterized by regulation of the dominant gut microbiota and normalization of key lipid metabolism‐related genes. This work highlights an association between oxygen‐bridged architecture and enhanced antioxidant nanozyme activity, while providing a potential design strategy for correcting lipid metabolic disorders through the gut‐liver axis.
Keywords: antioxidants, biomimetic synthesis, chlorinated paraffin, gut‐liver axis, lipid metabolism
Chlorinated paraffins (CPs) disrupt mitochondrial redox homeostasis, causing oxidative stress and gut‐liver axis dysfunction that ultimately drives lipid metabolic disorders. Inspired by natural Mn‐SOD, we developed oxygen‐bridged MIL‐100(Mn) nanozymes with enhanced SOD/CAT‐like cascade activity. Oral administration restored CP‐induced lipid metabolism by reprogramming gut microbiota and hepatic lipid‐related genes, highlighting oxygen‐bridged architectures as promising antioxidant designs.

1. Introduction
Chlorinated paraffins (CPs) are a class of artificially synthesized chlorinated alkanes widely used in industrial sectors, including plasticizers, flame retardants, and lubricants. They can be classified into short chain (SCCPs, C10‐13), medium chain (MCCPs, C14‐17), and long chain (LCCPs, C>17) based on their carbon chain length [1, 2, 3]. But they have been regarded as persistent organic pollutants (POPs) of global concern due to their persistence, bioaccumulation, and toxicity [4, 5, 6]. Among them, SCCPs included on the Stockholm Convention's restricted list in 2017 and MCCPs strictly restricted at SC COP‐12 (2025) have been demonstrated to exert substantial long‐term cumulative toxicity, damaging metabolic processes, the immune and reproductive systems, even causing liver and thyroid cancer, with a higher risk of human exposure [7, 8, 9, 10, 11]. Therefore, it is urgent and meaningful to conduct research on controlling the progression of chronic diseases caused by CPs to alleviate their long‐term health hazards.
In practical scenarios, CPs often appear mixed. Due to their hydrophobic nature, CPs could penetrate the cell membrane and accumulate within mitochondrial membranes, interfering with the electron transport chain [12, 13, 14, 15]. This disruption leads to electron leakage and excessive superoxide anion (•O2 −) production. The natural superoxide dismutase (SOD) in cells is overloaded, leading to imbalances in ROS generation and clearance. Subsequently, it destroys the antioxidant defense system, triggering oxidative stress and leading to mitochondrial dysfunction [16, 17]. Ultimately, ROS, as a trigger factor in lipid metabolic networks, disrupts lipid metabolism by inhibiting bile acid synthesis, fatty acid oxidation, and lipid clearance [18, 19, 20]. While the liver is the principal target of CP toxicity, emerging evidence indicates that CP‐induced lipid metabolic disorders are driven by disrupted crosstalk between gut microbial metabolism and hepatic lipid regulation along the gut‐liver axis [21, 22, 23, 24]. Mn‐SOD, as a mitochondria‐localized antioxidant enzyme with a distorted octahedral coordination geometry, represents a core endogenous defense that restores redox homeostasis and preserves normal cellular function under ROS‐driven metabolic stress induced by CPs [25, 26]. The simulation and supplementation functions of artificial antioxidant manganese‐based nanozymes, as well as their mild physiological effects, offer a potential solution [27, 28, 29, 30]. Simultaneously, with advances in gut microbiome profiling and transcriptomics, integrative analysis of the gut‐liver axis in controlling enterohepatic circulation provides a powerful and innovative paradigm for dissecting host‐microbe metabolic interactions [31, 32, 33, 34, 35, 36]. Therefore, it remains a major challenge and critical unanswered question how to efficiently eliminate CP‐induced harmful ROS to remodel the damaged gut‐liver axis and thereby govern enterohepatic lipid metabolic homeostasis.
Inspired by natural Mn‐SOD, we constructed octahedral MIL‐100(Mn), which enabled our research owing to its remarkable antioxidant properties and biocompatibility [37, 38, 39, 40, 41]. Compared with rod‐shaped Mn‐BTC, the unique µ 3‐oxo‐bridged trinuclear clusters in octahedral MIL‐100(Mn) provide abundant coordinatively unsaturated sites and efficient electron‐transfer channels, exhibiting higher SOD/CAT‐like activities. And the cascade of SOD/CAT activity effectively avoids the accumulation of toxic H2O2. Therefore, we employed MIL‐100(Mn) as a bioinspired redox modulator to interrogate and correct CP‐induced metabolic dysregulation along the gut‐liver axis. In vitro studies confirmed efficient cellular uptake of MIL‐100(Mn) by HepG2 cells, where it alleviated CP‐induced oxidative stress and restored cell viability. Following oral administration to high‐fat diet‐fed mice exposed to CPs, MIL‐100(Mn) strikingly ameliorated lipid metabolism‐related phenotypes. Integrated microbiome and liver transcriptomic analyses further revealed coordinated regulation of nine lipid‐associated gut microbial taxa and five key hepatic genes, as shown in Figure 1. This work highlights MIL‐100(Mn) as a bioinspired redox‐active nanozyme for integrating antioxidant regulation with modulation of the gut‐liver axis. Based on the reported MIL‐100 topology, we hypothesized that its multinuclear Mn coordination environment provides a relatively rigid catalytic pocket and influences the adsorption and conversion of ROS. The gut‐liver axis is a key vertical pathway in the complex regulatory networks of lipid metabolism. Unlike traditional research limited to a single perspective, the combination of multi‐omics techniques can elucidate the multi‐level mechanisms of metabolic regulation, providing a pathway for elucidating the regulatory associations and functional design of nanozymes in metabolic diseases.
FIGURE 1.

MIL‐100(Mn) alleviated CP‐induced gut microbiota dysbiosis and aberrant hepatic lipid metabolism through potential modulation of the gut‐liver axis. The underlying mechanism involved the enrichment of beneficial bacterial taxa, attenuation of ROS accumulation, and the regulation of key metabolic genes.
2. Results
2.1. Synthesis and Characterization of MIL‐100(Mn) and Mn‐BTC
Taking inspiration from the natural Mn‐SOD in mitochondria (PDB: 1N0J), MIL‐100(Mn) and Mn‐BTC were synthesized following a simple solvothermal method and a one‐pot method previously reported [42, 43], with a few modifications as illustrated in Figure 2A. Specifically, MIL‐100(Mn) was obtained by reacting Mn(NO3)2•4H2O and H3BTC with lauric acid as a modulator at 125°C for 3 h in a sealed autoclave. Mn‐BTC was prepared by mixing Mn(CH3COO)2•4H2O and H3BTC at 25°C for 15 h without any modulator. The elevated temperature and autogenous pressure in the solvothermal process promoted thermodynamic control, while lauric acid regulated nucleation and coordination kinetics, favoring the formation of ordered µ 3‐oxo‐bridged trinuclear clusters characteristic of MIL‐100(Mn). Consequently, MIL‐100(Mn) exhibits a rigid porous framework with multinuclear metal clusters, whereas Mn‐BTC forms a lower‐dimensional coordination polymer with mononuclear Mn centers and reduced structural connectivity. As shown in Figure S1, Mn‐BTC exhibits nanorod‐like growth. MIL‐100(Mn) is revealed to form a highly symmetrical octahedral morphology with an average size of approximately 600 nm, as observed in scanning electron microscopy (SEM) images and transmission electron microscopy (TEM) (Figure 2B,C). Fundamentally, it represents a macroscopic structural biomimetic by integrating essential motifs of native Mn‐SOD. The key elements include Asp160‐like carboxylate coordination, functionally accessible open metal sites derived from labile water, and a structurally rigid, constrained spatial pocket (Figure 2A). Furthermore, the high‐angle annular dark field scanning transmission electron microscopy (HADDF‐STEM) and corresponding element distribution energy dispersive spectroscopy (EDS) images indicated that Mn, C, and O elements are uniformly distributed (Figure 2D). There was no obvious segregation or clustering, indicating high microscale uniformity. Then, we analyzed their topological structure characteristics through powder X‐ray diffraction (XRD) spectra. As shown in Figure 2E, the diffraction peak positions are consistent with those previously reported [42, 43]. The different diffraction peak intensities at 10.37 and 20.82 degrees indicate the difference in their topological structures. Fourier transform infrared spectroscopy (FTIR) analysis showed that MIL‐100(Mn) and Mn‐BTC exhibited characteristic absorption peaks attributed to O─C─O stretching vibration at 1623 and 1568 cm−1 (Figure 2F). At the same time, the out‐of‐plane bending vibration peak of the aromatic ring C─H at 730 cm−1 was highly consistent with the typical spectral characteristics of the carboxylic acid aromatic ring in the 1,3,5‐phenyltrimethoic acid ligand [44, 45]. To clarify the oxidation state of metal active centers in nanomaterials, x‐ray photoelectron spectroscopy (XPS) was conducted. Figure S2 clearly confirm the composition of C, O, and Mn in MIL‐100(Mn) and Mn‐BTC, respectively. The high‐resolution Mn 2p spectrum in Figure 2G reveals that the characteristic peaks at 654.2 and 641.9 eV correspond to Mn 2p 3/2 and Mn 2p 1/2, respectively. The peak area fitting indicates that Mn exists in a mixed valence state. MIL‐100(Mn) exhibited a uniform Mn2+/Mn3+ mixed valence state (Mn2+/Mn3+ ≈ 0.97), facilitating efficient redox cycling. In contrast, Mn‐BTC shows a pronounced enrichment of Mn3+ species (Mn2+/Mn3+ ≈ 0.33), indicative of a less redox‐flexible coordination environment (Table S1). In addition, the O 1s spectrum can be deconvoluted into three distinct components corresponding to C═O, C─O, and Mn‐O (Figure 2H). MIL‐100(Mn) showed a more pronounced Mn‐O contribution than Mn‐BTC (Table S2). Collectively, the XRD, FTIR, and XPS results, together with the previously reported structure of MIL‐100(Mn), support classical MIL‐100‐type topology consistent with a µ 3‐oxo‐bridged trinuclear cluster coordination environment [46].
FIGURE 2.

Synthesis, characterization, and antioxidant enzyme‐like activities of manganese‐based nanozymes. (A) Process diagram for one‐pot synthesis of MIL‐100(Mn). The (B) SEM and (C)TEM images of MIL‐100(Mn) for morphology observation. (D) HAADF‐STEM and EDS for Mn, C, and O elements. (E) XRD patterns of the crystal phase and (F) FTIR spectra for MIL‐100(Mn) and Mn‐BTC. XPS spectra of MIL‐100(Mn) and Mn‐BTC: (G) Mn 2p and (H) O 1s. (I) Comparison of SOD‐like activity between MIL‐100(Mn) and Mn‐BTC, including inhibition rate curves fitted using the four‐parameter logistic curve, IC50 values, and SA. (J) Comparison of CAT‐like activity between MIL‐100(Mn) and Mn‐BTC, including K m and V max. They were fitted using the Michaelis‐Menten enzyme kinetics model. DFT‐calculated free energy diagrams of (K) SOD and (L) CAT‐like activity for MIL‐100(Mn) and Mn‐BTC. Data are presented as the mean ± SD (n = 3).
2.2. Comparison of Antioxidant Activity Between MIL‐100(Mn) and Mn‐BTC
Faithful simulation of native Mn‐SOD activity is intimately correlated with precise materials engineering and structural regulation. To assess the SOD‐like activity of MIL‐100(Mn) and Mn‐BTC, we used the WST‐8 system to test the SOD‐like activity of MIL‐100(Mn) and Mn‐BTC. Xanthine oxidase could catalyze the production of •O2 − from O2. Then, WST‐8 was oxidized to water‐soluble formazan dyes with an absorption maximum at 450 nm. Due to the ability to catalyze the dismutation of •O2 −, the activity of SOD is negatively correlated with the amount of formazan dyes. As demonstrated in Figure S3A, the UV–vis spectrum indicates a substantial decline at 450 nm following 20 min of reaction with 100 µg mL−1 of MIL‐100(Mn) and Mn‐BTC. Notably, MIL‐100(Mn) exhibited a more pronounced decrease (p = 0.0084), indicating its superior •O2 − scavenging ability. Then, we further monitored the absorbance changes of MIL‐100(Mn) with different concentrations within 1 h (Figure S3B). It demonstrated that absorbance varied according to concentration, and the reaction reached equilibrium after 20 min of initiation. We compared the •O2 − inhibition rates of MIL‐100(Mn) and Mn‐BTC at different concentrations for 20 min, as shown in Figure S3C. Once the concentration exceeded 25 µg mL−1, the inhibition rate of MIL‐100(Mn) was significantly higher than that of Mn‐BTC. When the concentration of MIL‐100(Mn) reached 100 µg mL−1, its inhibition rate exceeded 60%. Then, the absorbance (Figure S4) and inhibition rate (Figure 2I) for MIL‐100(Mn) and Mn‐BTC at varying concentrations were analyzed using the inhibition dose‐response curve. The half‐maximal inhibitory concentration (IC50) of MIL‐100(Mn) and Mn‐BTC was calculated to be 32.89 and 39.34 µg mL−1, respectively. Their corresponding SOD‐like activity are 152.95 and 127.10 U mg−1. It demonstrates that MIL‐100(Mn) exhibits a more substantial inhibitory effect than Mn‐BTC. In Figure S3D, MIL‐100(Mn) demonstrated higher SOD‐like activity under equal mass conditions. MIL‐100(Mn) shows a lower IC50 (higher potency) and higher SOD‐like activity compared to Mn‐BTC. The ESR test in Figure S5A,B demonstrated the time‐dependent •O2 − scavenging capabilities of MIL‐100(Mn) and Mn‐BTC. Figure S5C also confirms that MIL‐100(Mn) has a stronger •O2 − scavenging ability. In addition, we also compared the SOD‐like activity of MIL‐100 (Mn) and Mn BTC with some reported SOD nanozymes in Table S3.
Given that H2O2 is generated as a byproduct during SOD‐catalyzed dismutation of •O2 − and considering that nanozymes may induce Fenton‐like reactions leading to the formation of highly cytotoxic •OH, we further evaluated their catalase (CAT)‐like activity using the DA method [47, 48]. DA can be inhibited by H2O2 for self‐oxidation. Nanozymes with CAT‐like activity can decompose H2O2, relieving the inhibitory effect, while producing O2 to further promote DA oxidation, changing from orange to dark brown. In Figure S6A, We first tested that the optimal concentration of H2O2 for inhibiting DA oxidation was 20 mM and used it for subsequent evaluation. As shown by the increased absorbance at 405 nm in Figure S6B–D, both MIL‐100(Mn) and Mn‐BTC exhibits concentration‐dependent CAT‐like activity. The generation of bubbles with increasing time and concentration in Figure S7 also confirmed the decomposition of H2O2 by MIL‐100(Mn). And at the same concentration, MIL‐100(Mn) exhibited higher activity than Mn‐BTC (Figure S6E,F). This difference was associated with their distinct framework structures and Mn coordination environments [49]. The evaluation of CAT‐like activity in nanozymes is often complicated by interference from peroxidase activity (POD)‐like activity. In the DA method for testing CAT activity, the absorbance at 405 nm reflects DA oxidation, and the A450 nm/A480 nm ratio differentiates CAT‐like activity from potential side reactions. Then, we determined the A450 nm/A480 nm ratio in the system, which was greater than 1.4 across the 0–25 µg mL−1 range in Figure S8A,B. The absorbance at 652 nm in the TMB system indicates residual H2O2 or POD‐like activity. In Figure S8C, the absorbance at 652 nm decreased after the addition of H2O2, which also demonstrates that MIL‐100(Mn) preferentially decomposes H2O2, indicating dominant CAT‐like activity. Then, we monitored the changes in reaction absorbance at 405 nm within 3 min through enzymatic reaction kinetics experiments. As shown in Figure 2J, compared to Mn‐BTC, MIL‐100(Mn) has a higher V max (0.3612 mM min−1, ∼1.71 fold), but a slightly higher K m value (8.606 mM). According to Table S4, the metal content of MIL‐100(Mn) and Mn‐BTC was determined by ICP‐MS, and we further calculated their k cat. The turnover number of MIL‐100(Mn) is ∼2.32 times higher than Mn‐BTC, with k cat values of 0.1247 s−1 and 0.0537 s−1, respectively. This indicates faster H2O2 conversion per nominal Mn site under substrate‐saturating conditions. The relevant enzyme catalytic kinetic parameters are shown in Table S5. For heterogeneous nanozymes, the fitted K m is an apparent parameter influenced not only by substrate‐site interactions but also by H2O2 adsorption, external mass transfer, pore diffusion, framework partitioning, and active‐site accessibility. The ordered porous framework of MIL‐100(Mn) may therefore impose additional transport or partitioning requirements at relatively low H2O2 concentrations while providing a larger population of accessible catalytic sites or more rapid turnover after substrate access.
To elucidate the origin of the enzyme‐mimicking activities, density functional theory (DFT) calculations were performed to compare the reaction pathways of MIL‐100(Mn) and Mn‐BTC in both SOD and CAT reactions (Figures S9 and S10). For the SOD‐like pathway, superoxide disproportionation can be formally described through an Mn3+/Mn2+ redox cycle. In the oxidative half‐reaction, electron transfer from •O2 − to an Mn3 + center generates O2 and formally reduces Mn3 + to Mn2+. In the reductive half‐reaction, the reduced Mn2+ center transfers an electron to a second •O2 − species, which undergoes protonation and conversion into H2O2, thereby regenerating Mn3+. The Mn valence state cycle is shown in the following reaction equation and Figure S11.
In Figure 2K, the rate‐determining step (RDS) for Mn‐BTC is the adsorption of the second •OOH radical, which is a non‐spontaneous process with a ΔG of 0.163 eV. In contrast, this step on MIL‐100(Mn) is spontaneous (ΔG = ‐0.134 eV), and the RDS for MIL‐100(Mn) shifts to the decomposition of *‐O2‐H2O2 into *‐H2O2, with a minimal energy change of ‐0.008 eV. For the CAT‐like pathway, H2O2 adsorption and activation involve electron transfer between the peroxide‐derived intermediates and the Mn centers, followed by regeneration of the initial Mn oxidation state and release of H2O and O2. In Figure 2L, RDS is the initial adsorption of H2O2, which requires a lower free‐energy input on MIL‐100(Mn) (ΔG = 0.321 eV) than on Mn‐BTC (ΔG = 0.372 eV), indicating more favorable initial substrate activation. Although the second H2O2 is slightly more favorable on Mn‐BTC (ΔG = 0.154 eV) than on MIL‐100(Mn) (ΔG = 0.320 eV), the subsequent conversion from *‐O‐H2O2 to *‐H2O‐O2 is significantly more facile on MIL‐100(Mn), with a ΔG of −2.437 eV vs. −1.102 eV on Mn‐BTC. It is consistent with the results of enzyme kinetics experiments.
These results collectively demonstrate that MIL‐100(Mn) possesses superior antioxidant activities as observed experimentally. The difference in SOD‐like activity is mainly due to the dynamic provision of a more stable coordination pocket for intermediate species in the µ 3‐oxo‐bridged trinuclear clusters of MIL‐100(Mn). The mononuclear, flexible coordination environment of Mn‐BTC may be unable to effectively stabilize •OOH, resulting in higher intermediate energy and a higher reaction energy barrier. The CAT‐like activity lies in the thermodynamic control that drives the multinuclear synergistic effect in MIL‐100(Mn), thereby promoting the complete decomposition of H2O2. Therefore, we selected MIL‐100(Mn), which exhibited superior SOD and CAT‐like activity for further research. To investigate its stability in living organisms, we cultured MIL‐100(Mn) in simulated gastric (SGF) and intestinal fluids (SIF) for 2 h and 4 h, respectively. In Figure S12, the SOD/CAT‐like activity of MIL‐100(Mn) remained stable after incubation in simulated SGF and showed no reduction compared to the blank group (ddH2O). Although CAT‐like activity decreased after incubation in SIF, there were still concentration‐dependent differences.
2.3. The Reduction of MIL‐100(Mn) Nanozymes on ROS Storm Induced by CPs in Vitro
To further validate the cascade effect of SOD and CAT activities, we used the HRP/TMB method to determine the remaining H2O2 content in the supernatant, as shown in Figure 3A. The decrease in absorbance at 652 nm indicates that H2O2 is decomposed in the system, and MIL‐100(Mn) exhibited SOD‐like activity followed by CAT‐like activity, effectively avoiding the potential toxicity of H2O2. Subsequently, to validate the ROS‐mediated oxidative stress imbalance induced by SCCP and MCCP, as well as the cascade regulatory potential of MIL‐100 (Mn) shown in Figure 3B, we performed in vitro studies. As shown in Figure 3C,G,H, we found that MIL‐100(Mn) maintained cell viability above 80% at a concentration of 20 µg mL−1. In addition, to compare SCCP and MCCP simultaneously, we used the same concentration of 2500 µg mL−1. We used the fluorescent probe DCFH‐DA to measure intracellular ROS levels under various conditions (Figure 3D,I). SCCP and MCCP significantly increased intracellular ROS levels, approaching those of the Rosup positive control group. As shown in Figure 3E, regular intracellular SOD activity is difficult to balance the ROS accumulation caused by SCCP and MCCP, after treatment with MIL‐100(Mn), the total SOD activity increased ∼8.75‐fold significantly from 7.49 to 65.56 U mg−1, indicating its ability to eliminate ROS in vitro, as explained in Figure 3F. To eliminate the potential influence of released Mn ions, we adopted the MnCl2 treatment group (6.0877 µg mL−1) with the same Mn element concentration. As shown in Figure S13, the intervention of MnCl2 did not lead to a significant improvement in cellular SOD activity. In addition, Calcein AM/PI staining in Figure S14 was used to label live and dead cells, and the observed decrease in dead cells (red fluorescence) further demonstrates the salvage ability of MIL‐100(Mn). None of the experimental groups exhibited significant DNA damage (Figure S15).
FIGURE 3.

MIL‐100(Mn) exhibits intracellular antioxidant activity to regulate ROS imbalance caused by SCCP and MCCP. (A) Residual H2O2 was tested using HRP/TMB method after SOD/CAT reaction for different concentrations of MIL‐100(Mn). (B) Schematic diagram of the antioxidant cascade reaction pathway. (C) Cell viability tests of HepG2 cells after MIL‐100(Mn) treatment using the CCK‐8 assay. (D,I) Comparison of intracellular ROS fluorescence intensity under different conditions using the DCFH‐DA probe. (The scale bar indicates 100 µm.) (E) SOD activity in cells under various conditions. (F) Schematic diagram of Mn‐SOD/CAT‐like activity within cells. Cell viability tests of HepG2 cells under conditions of (G) SCCP, and (H) MCCP at different concentrations were performed using the CCK‐8 assay. Data are presented as the mean ± SD (n = 3) and calculated using one‐way ANOVA and multiple comparison tests (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001).
2.4. The Reversal of Phenotypic Levels Related to Lipid Metabolism in Vivo by MIL‐100(Mn) Nanozymes
Previous studies have demonstrated that CPs alter body and organ weights in mice fed normal diets [50]. Long‐term exposure to CPs is associated with an increased risk of T2D in obese individuals and may promote T2D development by disrupting lipid homeostasis [51]. Therefore, investigating the metabolic effects of CPs in a high‐fat diet (HFD) mouse model is essential to more accurately reflect susceptible metabolic states and elucidate how CP exposure synergizes with dietary lipid overload to exacerbate disturbances in lipid homeostasis. Having established the cellular antioxidant and cytoprotective effects of MIL‐100(Mn) in HepG2 cells, we next evaluated its effects on CP‐induced lipid metabolic abnormalities in an HFD‐fed mouse model. Unlike the in vitro experiments, the in vivo study enabled the investigation of systemic metabolic responses involving both the intestinal microbiota and the liver.
After a week of adaptive feeding, we conducted experiments on C57BL/6J mice under different dietary conditions and tested substances for 4 weeks (Figure 4A). To assess glucose metabolism, we performed an oral glucose tolerance test (OGTT) after a 4‐week intervention. According to Figure S16, there was no significant difference in fasting blood glucose (p = 0.0857) and AUC results (p = 0.9026) in mice after administration of MIL‐100(Mn). This indicates that MIL‐100(Mn) treatment did not significantly affect glucose homeostasis. Conversely, compared with the HFD group, the weight of mice in the CP group was significantly reduced. Oral intake of MIL‐100(Mn) nanozymes reversed the weight loss caused by CPs, and it was close to the HFD control group (Figure 4B,C). In addition, compared with the normal diet group, HFD can significantly increase body weight, perirenal/intrarenal fat, inguinal fat, and epididymal fat weight, while consuming CP can significantly reduce body weight, increase liver weight, and conversely change lipid metabolism‐related phenotypes (Figure S17). This indicates that we have successfully constructed a CP‐induced lipid metabolism abnormality model. After ingesting MIL‐100(Mn) nanozymes, a significant reversal effect was observed on the reduction of epididymal fat weight, brown fat weight, and visceral fat weight caused by CPs (Figure 4D–F). The blood lipid indicators showed that the serum levels of CHO, HDL, and LDL in the CP group were significantly increased compared with the HFD group, while MIL‐100(Mn) could significantly reverse the increase in blood lipid indicators, as shown in Figure 4G–J. Although there is a decrease in HDL levels, it may be a compensatory change or related to HDL clearance or functional abnormalities. The improvement of other indicators suggests that CPs can elevate blood lipid levels and promote lipid metabolic abnormalities in HFD, whereas MIL‐100(Mn) can significantly regulate lipid metabolism disorders. The liver is the core regulator of lipid metabolism. We found that liver weight in mice increased significantly after CPs ingestion compared with HFD (Figure 4K). We further performed a pathological analysis using H&E staining, as shown in Figure 4L. Numerous lipid droplets and inflammatory lesions were observed in the CP group, indicating that liver inflammation was driven by abnormal lipid metabolism. The pathological characteristics of the liver were significantly improved following MIL‐100(Mn) intervention. To determine whether MIL‐100(Mn) independently affected lipid metabolism under HFD conditions, serum lipid levels were also analyzed in the Mn group. As shown in Figure S18, MIL‐100(Mn) administration alone did not significantly alter serum TG, HDL, and LDL levels relative to the HFD group. These results suggest that the lipid improvements observed in the CPMn group were primarily associated with attenuation of the additional metabolic disturbance induced by CP exposure rather than a detectable general lipid‐lowering effect of MIL‐100(Mn) in HFD‐fed mice. This suggests the specificity of MIL‐100(Mn) in reversing CP‐induced lipid metabolism abnormalities.
FIGURE 4.

In vivo experiments and phenotype indicators of mice. (A) Experimental procedure. (B) Weekly body weight monitoring and (C) 4‐week body weight of mice. The indicators related to lipid metabolism include (D) perirenal/Infrarenal fat weight, (E) inguinal fat weight, (F) epididymal fat weight, (G) TG, (H) CHO, (I) HDL, and (J) LDL. (K) Liver weight and (L) representative H&E staining in HFD, CP, and CPMn groups. Data are presented as the mean ± SD (n = 6) and calculated using one‐way ANOVA and multiple comparison tests (ns represents not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001).
2.5. The Regulation of Gut Microbiota Related to Lipid Metabolism Disorders Induced by CPs in Vivo
CPs could disrupt the gut microbiota in mice [52]. To investigate the effect of MIL‐100(Mn) nanozymes on the composition of mouse gut microbiota, we conducted high‐throughput 16S rRNA gene sequencing targeting the V3‐V4 region [53, 54]. Figure S19 shows the overlap and differences in gut microbiota composition among HFD, CP, and CPMn groups at the amplicon sequence variant (ASV) level. The Venn diagram visually presents the shared and unique microbial communities among them (Figure S19A). Principal coordinate analysis (PCA) based on the Bray‐Curtis distance matrix in Figure S19B revealed differences in β‐diversity of gut microbiota composition and in sample clustering within the groups. The sample points from different groups exhibit a clear separation trend in the PCA coordinate space. CPs were primarily distributed in the negative regions of PC1 and PC2, whereas CPMn were clustered mainly in the positive areas near the control group. This indicated that the MIL‐100(Mn) intervention altered the overall structure of the gut microbiota influenced by CPs. Additionally, the heatmap showed a white and light purple diagonal region, indicating the relative stability of the microbial community composition within the group (Figure S19C). We then analyzed the richness and diversity of the gut microbiota using α‐diversity analysis. Compared to the HFD group, the Chao1 and Shannon indices of gut microbiota in the CP group were significantly higher. However, when treated with MIL‐100(Mn), these indices decreased toward the levels observed in the HFD group (Figure 5A,B). This indicated that CP could create ecological niches for more microorganisms and disrupt microbial balance, while MIL‐100(Mn) effectively mitigated this disorder.
FIGURE 5.

Composition of differential gut microbiota. (A) Chao1 index and (B) Shannon index in α‐diversity analysis. Analysis of microbial composition at the (C) phylum level and (D) genus level. (E) Dominant bacterial taxa in HFD, CP, and CPMn groups. Data are presented as the mean ± SD (n = 5).
After classifying and annotating microbial species at the phylum and genus levels, it was observed that the mouse gut microbiota is predominantly composed of Firmicutes, Actinobacteria, and Bacteroidetes (>95%). In Figure 5C, the addition of CPs resulted in a decrease in Firmicutes and an increase in Actinobacteria, while the number of Bacteroidetes was similar to that of the HFD group. Short‐chain fatty acids (SCFAs) are important microbial metabolites involved in intestinal epithelial energy metabolism and barrier homeostasis. Certain members of the phylum Firmicutes have been reported to participate in SCFA production [55]. Under the intervention of MIL‐100(Mn), the number of Firmicutes and F/B values in the CPMn group returned to the HFD group (Figure S19D). This suggests the potential effects of downstream SCFAs.
At the genus level, we identified the Top 10 dominant differential bacterial genera (Figure 5D), including Lactobacillus, Romboutsia, Faecalibaculum, Ileibacterium, Dubosiella, Enterorhabdus, Lactococcus, Erysipelatoclostridium, Clostridium_sensu_stricto_1, and uncultured. The cladogram of evolutionary branching in Figure 5E shows the positions of significantly enriched microorganisms in each group in the phylogenetic tree. The sankey diagram in Figure S19E visually displays the source distribution and relative abundance contribution of different bacterial genera in different groups. This indicates that the intervention of MIL‐100(Mn) has expanded the diversity of beneficial bacteria and broad‐spectrum positively regulated the gut microbiota, making the gut microbiota more stable and resistant to interference. The relative abundance of Top 1 Lactobacillus increased following MIL‐100(Mn) treatment (Figure 6A). Previous studies have associated certain Lactobacillus species with bile acid transformation and cholesterol metabolism. Therefore, the observed abundance change may be related to the concurrent alterations in serum cholesterol [56, 57, 58]. Nie et al. have reported that Romboutsia and Faecalibaculum are involved in short‐chain fatty acid production, particularly butyric acid, which is closely associated with anti‐inflammatory effects [59]. As shown in Figure 6B,C, the relative abundances of Romboutsia and Faecalibaculum shifted toward the levels observed in the HFD group, which suggests a potential relationship with downstream microbial metabolic alterations.
FIGURE 6.

The relative abundance of the TOP 10 different gut microbiota at the genus level: (A) Lactobacillus, (B) Romboutsia, (C) Faecalibaculum, (D) Ileibacterium, (E) Dubosiella, (F) Enterorhabdus, (G) Lactococcus, (H) Erysipelatoclostridium, and (I) Clostridium_sensu_stricto_1. (J) Correlation heatmap of advantageous gut microbiota within and among groups. Data are presented as the mean ± SD (n = 5) and calculated using one‐way ANOVA and multiple comparison tests (ns represents not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001).
This relates to its potential anti‐inflammatory properties, particularly its capacity to produce butyric acid. In addition, the decrease in Enterorhabdus and Lactococcus and the increase in Erysipelatoclostridium and Clostridium_sensu_stricto_1 to the HFD group also demonstrate that MIL‐100(Mn) can attenuate the disruption of gut microbiota composition in mice induced by CPs (Figure 6F–I). However, Figure 6D,E indicate that the relative abundance of Ileibacterium and Dubosiella did not show a significant recovery. The relevant heatmap in Figure 6J also visually illustrates the changes in beneficial gut microbiota within and between groups.
Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2) is commonly used to predict the functional composition of microbial communities from 16S rRNA gene sequencing data, addressing the limitation of amplicon sequencing that cannot directly measure functional gene information [60, 61]. Therefore, we found that the differential microbial pathways between HFD and CP groups were mainly enriched in Galactose metabolism and Butanoate metabolism (Figure S20A). Meanwhile, the microbial pathways distinct between the CPMn and CP groups were enriched for pathways related to glucose and lipid metabolism. These include Glycerophospholipid metabolism, Butanoate metabolism, the TCA cycle, fatty acid degradation, galactose metabolism, steroid biosynthesis, steroid hormone biosynthesis, pentose and glucuronate interconversions, C5‐branched dibasic acid metabolism, biosynthesis of unsaturated fatty acids, secondary bile acid biosynthesis, primary bile acid biosynthesis, glyoxylate and dicarboxylate metabolism, and ascorbate and aldarate metabolism (Figure S20B). It indicates a potential association between differential gut microbiota and phenotypic indicators, including body weight, glucose tolerance, TG, TC, HDL, and LDL.
Therefore, to investigate the relationship between gut microbiota alterations and lipid metabolic phenotypes, we conducted additional correlation analyses, as shown in Figure 7B. The significance is mainly reflected in the blood biochemical indicators of Enterorhabdus and HDL. Enterorhabdus is positively correlated with CHO, LDL, and liver weight, while negatively correlated with inguinal fat and perirenal/infrarenal (P/I) fat. For HDL, there is a positive correlation with Faecalibaculum and Dubosiella, whereas a negative correlation is observed with Romboutsia, Erysipelatoclostridium, Lactococcus, and Clostridium_sensu_stricto_1. Additionally, there are positive correlations between epididymal fat and Romboutsia, and between body weight and Erysipelatoclostrium, and a negative correlation between inguinal fat and Lactococcus. This indicates a potential interaction between gut microbiota and lipid metabolism.
FIGURE 7.

Transcriptomic and multi‐omics interaction analysis. (A) Annotations of DEGs in HFD, CP, and CPMn groups based on the KEGG pathways for CPMn vs CP. Correlation interaction analysis between (B) differential gut microbiota and lipid metabolism indicators, (C) liver transcriptome DEGs and lipid metabolism indicators, and (D) gut microbiome and liver transcriptome. Correlation analysis using OmicStudio tool https://www.omicstudio.cn/tool (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001).
2.6. The Transcriptome Analysis Related to Lipid Metabolism at the Genetic Level
The liver is the core site of lipid metabolism, capable of synthesizing and decomposing fat, and precisely regulating lipid homeostasis [62]. Liver cells can synthesize endogenous CHO, TG, and apolipoproteins, which assemble into VLDL and enter the bloodstream. And here, LPL hydrolyzes lipoprotein‐TG. Then, it promotes mitochondrial β‐oxidation to provide energy to the liver [63]. Moreover, CYP7A1 catalyzes the rate‐limiting conversion of cholesterol in the classical bile acid synthesis pathway, making it one of the important transcriptional indicators of bile acid metabolism [64].
To further explore the metabolic changes in the liver under various treatment conditions, we performed transcriptome analysis. As volcanic maps shown in Figure S21A,B, there are 2517 differentially expressed genes (DEGs) between the CP and HFD groups, including 1078 upregulated genes and 1439 downregulated genes (log2|fold change| > 1, p < 0.05). Compared with CP, CPMn has 75 upregulated and 314 downregulated genes (log2|fold change| > 1, p < 0.05) (Figure S21C). The heatmap in Figure S21D showed that the expression patterns of a subset of hepatic genes differed between the CP and CPMn groups, including genes annotated to metabolic pathways. Through Reactome analysis in Figure S21E, we found that DEGs (>100) are concentrated in pathways related to metabolism, signal transduction, protein metabolism, and the immune system. KEGG analysis revealed that DEGs related to metabolism are enriched in lipid metabolism pathways (Figure 7A). The DEGs in lipid metabolism include Akr1c18, Cyp7a1, Cyp2b13, Cyp2b9, and Lpl. We subsequently performed correlation analyses to explore the statistical associations between the major DEGs and metabolic phenotypes (Figure 7C). Significant correlations were observed for several phenotypic indicators, whereas no significant association was detected with HDL. Cholesterol 7α‐hydroxylase (CYP7A1) is at the initial and rate‐limiting step in classical bile acid synthesis [65, 66]. Interestingly, Cyp7a1 shows positive correlations with body weight, inguinal fat, P/I fat, and epididymal fat, and negative correlations with CHO, LDL, and liver weight. The other four DEGs show opposite regulation from Cyp7a1. In addition, there are strong correlations between DEGs and differential microbiota, as shown in Figure 7D. These cross‐dataset associations suggest a possible coordination between changes in gut microbiota and liver gene expression profiles under MIL‐100(Mn) intervention.
2.7. Biological Safety Evaluation for MIL‐100(Mn) Nanozymes
The biosafety of nanozymes has attracted considerable interest due to their potential for subsequent clinical applications. As novel materials that simulate natural enzyme activity, nanozymes have demonstrated significant potential for disease diagnosis and treatment [67, 68]. However, their non‐physiological catalytic activity, metal ion release, and long‐term accumulation characteristics in vivo may lead to potential cytotoxicity, immunogenicity, or organ damage. Therefore, we evaluated the biosafety of MIL‐100(Mn) both in vivo and in vitro.
Through the rabbit red blood cell hemolysis test in Figure S22A, we found that MIL‐100(Mn) concentrations in the range of 5–500 µg mL−1 did not cause significant hemolysis. This demonstrated the superior biocompatibility of MIL‐100(Mn). To further analyze the cytotoxicity of nanozymes at the effective concentration for ROS inhibition in vitro, we used Calcein/PI staining to assess cell morphology. As shown in Figure S14, SCCP and MCCP groups showed significant cell death, while the MIL‐100(Mn) group maintained original cell viability after 24 h of treatment. Notably, the cell viability of SCCP and MCCP groups was restored after administration of MIL‐100(Mn). This indicates that the MIL‐100(Mn) nanozyme not only exhibits relative biological safety but can also rescue cells from CP‐induced cell death. In addition, we measured residual Mn element in different organs using ICP‐MS, as shown in Figure S21B and Table S6. The results indicate that nanozymes are mainly distributed in the liver, suggesting their metabolic regulatory function. Similarly, we performed H&E staining and histopathological analysis for the liver, kidney, colon, and testis (Figure S22C–G). The results showed that MIL‐100(Mn) administration did not significantly increase the histopathological scores of the liver, kidney, colon, and testicular tissues, compared with the HFD group (p > 0.05). It supports the absence of detectable tissue injury attributable to MIL‐100(Mn) under the present experimental conditions. CP exposure was associated with qualitative trends toward inflammatory changes and disruption of colonic mucosal architecture. Although there was no significant difference in the semi‐quantitative histopathological scores among the groups, this provides preliminary evidence that MIL‐100(Mn) has good biocompatibility and the ability to combat metabolic diseases.
3. Conclusion and Discussion
In summary, this work elucidates a novel perspective of biomimetic antioxidant oxygen‐bridged nanozyme regulating lipid metabolic disorders induced by CPs through alleviating excessive ROS generation, reducing oxidative stress, and subsequently regulating crosstalk along the gut‐liver axis. The biomimetic MIL‐100(Mn) nanozyme was inspired by mitochondrial Mn‐SOD. The µ 3‐oxo‐bridged trinuclear Mn clusters endow the framework with a Mn‐SOD‐like coordination environment, high density of accessible active sites, and hierarchical porosity, collectively enabling efficient catalytic cycling. Compared with disordered Mn‐BTC, MIL‐100(Mn) exhibited significantly enhanced SOD‐like activity and, importantly, a cascade CAT‐like function with ∼2.32‐fold higher k cat than Mn‐BTC, which prevented secondary oxidative damage caused by H2O2 accumulation. This tandem redox regulation effectively restored intracellular antioxidant capacity, as evidenced by the 8.75‐fold increase in intracellular SOD activity, and reversed CP‐induced lipid metabolic abnormalities in vivo. Beyond direct ROS scavenging, multi‐omics analyses revealed that the therapeutic effect of MIL‐100(Mn) is closely associated with coordinated reprogramming of the gut‐liver axis, involving modulation of dominant gut microbiota and normalization of key lipid metabolism‐related genes. These findings highlight the µ 3‐oxo‐centered Mn cluster as a critical structural determinant governing nanozyme activity and biological function.
Several limitations should be acknowledged. Although the proposed µ 3‐oxo‐centered Mn cluster is supported by relevant characterization, the local Mn coordination structure can be verified through further detailed characterization. This study provides a preliminary reference for future research on the gut‐liver axis pathway of lipid metabolism. Further work should move toward more direct verification of causal mechanisms at the genetic level, including targeted knockout or silencing of key regulators to dissect causal links between ROS modulation and lipid metabolic reprogramming. The risks associated with long‐term exposure to low‐dose CPs need to be evaluated separately. From the perspective of downstream metabolism, further fecal transplantation or targeted metabolite measurements of candidate microbial metabolites such as SCFA can be adopted. In parallel, elucidating the long‐term fate and biodegradation of nanozymes will be essential for clinical translation. Therefore, in the future, more advanced characterization techniques, targeted metabolomics, and microbiota‐guided interventions can be used to clarify the global regulatory mechanisms.
4. Experimental Section
4.1. Materials
Mn(NO3)2•4H2O, Mn(CH3COO)2•4H2O, H3BTC, and lauric acid were purchased from Aladdin (China). DMEM, 0.9% saline, and glucose were obtained from Solarbio (China). Fetal bovine serum (FBS) was purchased from PAN (Germany). MnCl2 and 0.25% trypsin were purchased from Adamas (China). Industrial‐grade CPs were sourced from a local market in Haidian District, Beijing, China. SCCP (C10‐13, 55.5% Cl) and MCCP (C14‐17, 52% Cl) were obtained from Tianjin Alta Technology Co., Ltd. (China). Artificial gastric and intestinal fluids were acquired from Yuan Ye Biotechnology Co., Ltd. (China). The SOD detection kit, ROS detection kit (DCFH‐DA), cell viability assays, Calcein‐AM, Propidium iodide (PI), DNA damage detection kit, and BCA protein assay kits were obtained from Shanghai Beyotime Biotechnology Co., Ltd. (Shanghai, China).
Experiments were performed using a Teflon‐lined reaction vessel, oven (Shanghai Shangpu Instrument Equipment Co., China), tabletop high‐speed refrigerated centrifuge (Eppendorf, Germany), RA‐1000 clinical chemistry analyzer (Technicon, USA), ultrasonic cleaner (Shenzhen Jiemeng Technology Co., China), fluorescence microscope (Carl Zeiss, Germany), inductively coupled plasma mass spectrometer (Thermo Scientific, USA), heating magnetic stirrer (Dalongxingchuang Lab Equipment Co., China), microplate reader (Thermo Fisher Scientific, USA), multi‐functional microplate reader (TECAN, Switzerland) and blood glucose meter (Roche, Germany).
4.2. Synthesis of MIL‐100(Mn)
Dissolve 0.12 mmol of Mn(NO3)2•4H2O and 0.475 mmol of H3BTC in 25 mL of methanol and add 2.25 mmol of lauric acid as a regulator. Under magnetic stirring at 800 rpm, continuously mix the solution for 10 min to ensure uniformity. Next, transfer the mixture into a 50 mL stainless steel autoclave lined with polytetrafluoroethylene and process it at 125°C in a temperature‐controlled oven for 3 h. After the reaction is complete, allow the autoclave to cool to room temperature, then separate the precipitate by centrifugation at 8000 rpm and wash it three times with ethanol. Finally, vacuum‐dry the brown product at 60°C for 3 h.
4.3. Synthesis of Mn‐BTC
Dissolve 5 mmol of Mn(CH3COO)2•4H2O in 50 mL of water and 15 mmol of H3BTC in 150 mL of ethanol. Then, mix the two solutions and stir magnetically at 25°C for 15 h. After the reaction, collect the white solid by centrifugation at 8000 rpm, wash it three times with ethanol, and dry at 60°C for 12 h.
4.4. SOD‐Like Activity
The SOD‐like activity of the samples was measured using a total superoxide dismutase assay kit based on the WST‐8 method (Beyotime, S0101). The tests were conducted following the original protocol with minor modifications. First, combined MIL‐100(Mn) or Mn‐BTC solutions of different concentrations with 160 µL of the working solution, then added varying amounts of SOD buffer to bring the total volume to 180 µL. Finally, added 20 µL of reaction starter solution and mixed at 37°C for 20 min. Use the microplate reader to measure absorbance changes at 450 nm. The Equation (1) for calculating the inhibition rate of superoxide anions (•O2 −) is as follows:
| (1) |
Among them, blank 1 is the blank control group without nanozyme samples, and blank 2 is the blank control group without the reaction starter solution.
According to the above process, the absorbance changes and inhibition rates of nanozyme samples at different concentrations were measured separately, and the half inhibitory concentration (IC50) was calculated using the dose‐response inhibition function analysis in GraphPad Prism 10 software. The amount of nanozyme needed to achieve a 50% inhibition rate under these specific conditions is defined as 1 unit of SOD‐like activity. The calculation Equation (2) for SOD enzyme activity is as follows [69]:
| (2) |
Among them, V is the total volume of the reaction system.
4.5. CAT‐Like Activity
Catalase (CAT)‐like activity was evaluated using a colorimetric dopamine (DA) assay. Typically, the reaction system contained Tris buffer (10 mM, pH 8.5), 20 mM H2O2, nanozymes with different concentrations, and 1 mg mL−1 DA solution. After adding the reaction mixture to a 96‐well plate, incubated at 37°C for 20 min. The absorbance at 405 nm and 480 nm was subsequently recorded to assess CAT‐like activity. To eliminate the contribution of OXD‐like activity, ΔA405 nm was calculated using the following Equation (3):
| (3) |
Among them, A1, A2, A3, and A4 denote the absorbances at 405 nm for the DA, DA+H2O2, DA+H2O2+Sample, and DA+Sample groups, respectively.
According to the above process, the absorbance change rate v 0 (mM min−1) under different concentrations of H2O2 substrate conditions was measured separately. The reaction kinetics parameters K m (mM) and V max (mM min−1) of MIL‐100(Mn) and Mn‐BTC were fitted by the Michaelis‐Menten equation in GraphPad Prism 10 software. The k cat value is calculated according to the following Equation (4):
| (4) |
Among them, V max is the maximum enzymatic reaction rate (M s−1), and [E]t is the density of nanozyme active centers (µM). The density of active centers is converted based on the metal content of the Mn element determined by ICP‐MS.
4.6. Intracellular SOD Activity Test
Intracellular SOD activity was measured using the SOD assay kit (Beyotime, S0101). Cells (2 × 105 cells per well) were plated in 6‐well plates and treated according to the experimental groups: Blank, SCCP, SCCP + MIL‐100(Mn), MCCP, MCCP + MIL‐100(Mn), and MIL‐100(Mn). After treatment, cells were washed with cold PBS, trypsinized, and collected. The cell lysate was prepared with SOD sample solution, vortexed, and centrifuged at 12 000 g for 5 min at 4°C. The supernatant was used to measure SOD activity. Protein concentration was determined by the BCA assay (Beyotime, P0012).
4.7. Intracellular ROS Scavenging Detection
HepG2 cells (5 × 104 cells per well) were cultured in 12‐well plates. After 24 h, they were treated separately with SCCP, MCCP, MIL‐100(Mn), SCCP + MIL‐100(Mn), and MCCP + MIL‐100(Mn) and incubated for more than 6 h. Before probe loading, the cells were stimulated with the Rosup positive control for 30 min. Then, they were incubated with 10 µM DCFH‐DA for 30 min to measure intracellular ROS levels. Subsequently, the cells were washed and observed under a fluorescence microscope (IX71, Olympus, Japan).
4.8. In Vivo Treatment of Lipid Metabolism Abnormalities Induced by CPs in Mice
Six‐week‐old male C57BL/6J mice were obtained from Beijing Vitality River Laboratory Animal Technology Co. and approved by the Animal Ethics Committee of China Agricultural University (Ethical approval number: Aw11404202‐4‐3). They were housed in the SPF animal room of the Beijing Agricultural Products Quality Supervision, Inspection, and Testing Centre of the Ministry of Agriculture. After one week of adaptive feeding, mice were divided into groups, including Control (a normal diet group), HFD (high‐fat diet feeding), Mn (HFD + MIL‐100(Mn), 10 mg kg−1), CP (HFD + CPs feeding, 1000 mg kg−1), and CPMn [HFD + CPs, 1000 mg kg−1 + MIL‐100(Mn), 10 mg kg−1] groups. The chlorinated paraffin used in this study was an industrial‐grade CP mixture, which was selected to reflect the compositional complexity of commercially available CP products. The exposure concentrations were selected on the basis of preliminary experiments and previously reported CP toxicological models to establish reproducible experimental models [21, 70]. The test substance was administered orally daily for 4 weeks, and body weight was recorded weekly. Fecal samples were collected from mice before euthanasia and immediately stored in liquid nitrogen for subsequent microbiota analysis.
4.9. Fecal Microbiome Analysis
Fecal genomic DNA was extracted using the E.Z.N.A. Soil DNA Kit (Omega Bio‐Tek, Inc., USA) according to the manufacturer's protocol. The V3‐V4 region of the bacterial 16S rRNA gene was amplified using universal primers 338F (5’‐ACTCCTACGGGAGGCAGCAG‐3’) and 806R (5’‐GGACTACHVGGGTWTCTAAT‐3’). The PCR products were processed for library construction using the NEB Next Ultra II DNA Library Prep Kit (New England Biolabs, Inc., USA). Deep sequencing was performed on the Illumina MiSeq/Novaseq platform at Allwegene Technologies (Beijing). Linear discriminant analysis effect size (LEfSe) was used to identify significantly different bacterial taxa (p‐value < 0.05, LDA score > 4). Functional profiles of the microbiome were predicted using PICRUSt2, and statistical significance was assessed using STAMP.
4.10. Transcriptomic Analysis of Liver
Liver transcriptomic analysis was performed at Shanghai Majorbio Bio‐Pharm Technology Co., Ltd. RNA was purified, reverse transcribed, and libraries were constructed for sequencing. Differential expression analysis was conducted using DESeq2 or DEGseq. Genes with |log2FC| ≥ 1 and FDR ≤ 0.05 (DESeq2) or FDR ≤ 0.001 (DEGseq) were considered significantly differentially expressed genes (DEGs). Enrichment and intersection analyses of Reactome and KEGG pathways were performed, with Bonferroni‐corrected p‐values ≤ 0.05 considered statistically significant.
4.11. Statistical Analysis
The raw 16S rRNA gene sequencing and liver RNA‐sequencing data generated in this study have been deposited in the NCBI Sequence Read Archive (SRA) under BioProject accession number PRJNA1533422. Data are presented as mean ± standard deviation (SD), plotted using GraphPad Prism 10 software. Statistical significance was evaluated by an unpaired Student's two‐sided t‐test. Significance between multiple samples was assessed using one‐way ANOVA. The post hoc analysis of variance was conducted using Tukey's multiple comparisons test. Among them, ns represents not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Advanced Cor link was performed using the OmicStudio tools at https://www.omicstudio.cn/tool.
Author Contributions
Qi Zhang: methodology, validation, formal analysis, investigation, data curation, writing – original draft, visualization. Wenxuan Jiang: methodology, validation, writing – review and editing, formal analysis, investigation. Yanan Wang: methodology, validation, writing – review and editing. Shujun Dong: supervision, resources, writing – review and editing. Boran Li: investigation, writing – review and editing. Yujia Cai: methodology, resources. Ruiqing Ke: investigation. Tianyi Ma: investigation. Xin Wang: writing – review and editing. Kunlun Huang: supervision, project administration, funding acquisition. Yunbo Luo: supervision, funding acquisition, project administration. Chengzhou Zhu: conceptualization, resources, supervision, project administration, funding acquisition, writing – review and editing. Nan Cheng: conceptualization, resources, supervision, project administration, funding acquisition, writing – review and editing.
Funding
The 2115 Talent Development Program of China Agricultural University.
Conflicts of Interest
The authors declare no conflicts of interest.
Supporting information
Supporting File: advs78792‐sup‐0001‐SuppMat.docx.
Acknowledgements
The authors gratefully acknowledge the financial support of 2115 Talent Development Program of China Agricultural University.
Contributor Information
Chengzhou Zhu, Email: czzhu@ccnu.edu.cn.
Nan Cheng, Email: chengnanfsne@cau.edu.cn.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Chen W. F., Liu J. Y., Hou X. W., and Jiang G. B., “A Review on Biological Occurrence, Bioaccumulation, Transmission and Metabolism of Chlorinated Paraffins,” Critical Reviews in Environmental Science and Technology 54, no. 5 (2024): 424–443, 10.1080/10643389.2023.2246615. [DOI] [Google Scholar]
- 2. Ma Y., Li Q., Su G., et al., “Occurrence and Remediation of Chlorinated Paraffins in Global Environmental Matrices: Levels, Trends, and Future Prospects,” Critical Reviews in Environmental Science and Technology 55, no. 23 (2025): 1730–1756, 10.1080/10643389.2025.2566941. [DOI] [Google Scholar]
- 3. Mendo Diaz O., Tell A., Knobloch M., et al., “Fingerprinting of Chlorinated Paraffins and Their Transformation Products in Plastic Consumer Products,” Chemosphere 338 (2023): 139552, 10.1016/j.chemosphere.2023.139552. [DOI] [PubMed] [Google Scholar]
- 4. Yu J., Tang Q., Yin G., et al., “Uptake, Accumulation and Toxicity of Short Chain Chlorinated Paraffins to Wheat (Triticum Aestivum L.),” Journal of Hazardous Materials 464 (2024): 132954, 10.1016/j.jhazmat.2023.132954. [DOI] [PubMed] [Google Scholar]
- 5. He W., Sun P., Zhao Y., et al., “Source Toxicity Characteristics of Short‐ and Medium‐chain Chlorinated Paraffin in Multi‐environmental media: Product Source Toxicity, Molecular Source Toxicity and Food Chain Migration Control through Silica Methods,” Science of the Total Environment 876 (2023): 162861, 10.1016/j.scitotenv.2023.162861. [DOI] [PubMed] [Google Scholar]
- 6. Cui L., Gao L., Zheng M., et al., “Bioaccessibility of Short Chain Chlorinated Paraffins in Meat and Seafood,” Science of the Total Environment 668 (2019): 996–1003, 10.1016/j.scitotenv.2019.03.043. [DOI] [PubMed] [Google Scholar]
- 7.“Chlorinated Paraffins,” “IARC Monographs on the Evaluation of Carcinogenic Risks to Humans,” 48, (1990): 55. [PMC free article] [PubMed] [Google Scholar]
- 8. Chen C., Chen A., Li L., Peng W., Weber R., and Liu J., “Distribution and Emission Estimation of Short‐ and Medium‐Chain Chlorinated Paraffins in Chinese Products through Detection‐Based Mass Balancing,” Environmental Science & Technology 55, no. 11 (2021): 7335–7343, 10.1021/acs.est.0c07058. [DOI] [PubMed] [Google Scholar]
- 9. Yu Z. H., Mu Y. W., Du Y. C., and Zeng T., “Environmental Occurrence, human Exposure Routes, Toxicity, and Risk Assessments of Medium‐chain Chlorinated Paraffins (MCCPs): a Comprehensive Review,” Archives of Toxicology 99, no. 9 (2025): 3463–3483, 10.1007/s00204-025-04106-z. [DOI] [PubMed] [Google Scholar]
- 10. Liu Y., Aamir M., Li M., et al., “Prenatal and Postnatal Exposure Risk Assessment of Chlorinated Paraffins in Mothers and Neonates: Occurrence, Congener Profile, and Transfer Behavior,” Journal of Hazardous Materials 395 (2020): 122660, 10.1016/j.jhazmat.2020.122660. [DOI] [PubMed] [Google Scholar]
- 11. Conference of the Parties to the Stockholm Convention , “Listing of Medium‐Chain Chlorinated Paraffins,” in Decisions Adopted by the Conferences of the Parties to the Stockholm Conventions on Persistent Organic Pollutants at the Tweltth Meeting, Decision SC‐12/10, UNEP/POPS/COP.12/32/Add.1, Geneva, Switzerland, 28 April to 9 May 2025.
- 12. Wang X., Zhu J., Xue Z., Jin X., Jin Y., and Fu Z., “The Environmental Distribution and Toxicity of Short‐chain Chlorinated Paraffins and Underlying Mechanisms: Implications for Further Toxicological Investigation,” Science of the Total Environment 695 (2019): 133834, 10.1016/j.scitotenv.2019.133834. [DOI] [PubMed] [Google Scholar]
- 13. Ren X., Geng N., Zhang H., et al., “Comparing the Disrupting Effects of Short‐, Medium‐ and Long‐Chain Chlorinated Paraffins on Cell Viability and Metabolism,” Science of the Total Environment 685 (2019): 297–307, 10.1016/j.scitotenv.2019.05.388. [DOI] [PubMed] [Google Scholar]
- 14. Huang C., Chen S., Cheng L., et al., “Mitochondrial Metabolomics Reveals the Mechanism of SCCP Induced Energy Metabolism Inhibition,” Environmental Science & Technology 60, no. 10 (2026): 7665–7676, 10.1021/acs.est.5c12098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Geng N., Chen S., Bian Y., et al., “Uncovering Mitochondrial Defects Induced by Chemicals: a Case Study of Low‐Dose Medium‐Chain Chlorinated Paraffin Exposure,” Environmental Science & Technology 59, no. 18 (2025): 8972–8983, 10.1021/acs.est.4c09460. [DOI] [PubMed] [Google Scholar]
- 16. Cheng L., Li F., Luo Y., et al., “Medium‐Chain Chlorinated Paraffins Induced Reproductive Toxicity in Female Rats by Interfering with Oocyte Meiosis and Triggering DNA Damage,” Environmental Science & Technology 59, no. 23 (2025): 11455–11467, 10.1021/acs.est.4c12668. [DOI] [PubMed] [Google Scholar]
- 17. Do S. D. and Rhee J. S., “Exposure to Short‐chain Chlorinated Paraffins Induces Mortality in Marine Medaka Larvae through Neurotoxicity and Oxidative Stress,” Journal of Hazardous Materials 494 (2025): 138531, 10.1016/j.jhazmat.2025.138531. [DOI] [PubMed] [Google Scholar]
- 18. Jiang S., Kim T. M., Park S. Y., and Jin E. J., “ROS‐responsive MnO2 Mesoporous Hydrogel to Modulate Liver‐muscle Crosstalk and Mitigate NAFLD‐associated Sarcopenia via Exosomal miR‐582‐5p Delivery,” Theranostics 15, no. 10 (2025): 4579–4592, 10.7150/thno.108280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Cheng L., Chen S., Luo Y., et al., “Medium‐Chain Chlorinated Paraffins Trigger Thyroid Hormone Synthesis and Interfere with Mitochondrial Function in the Thyroid Gland,” Environmental Science & Technology 58, no. 35 (2024): 15428–15437, 10.1021/acs.est.4c01341. [DOI] [PubMed] [Google Scholar]
- 20. Chen J., Yang H., Qin Y., Zhou X., and Ma Q., “Tryptophan Ameliorates Metabolic Syndrome by Inhibiting Intestinal Farnesoid X Receptor Signaling: the Role of Gut Microbiota–Bile Acid Crosstalk,” Research 7 (2024): 0515, 10.34133/research.0515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Wang Y., Dong S., Zhang Q., et al., “Longitudinal Multi‐omics Decipher Chlorinated Paraffin 52 Disruption of Gut‐brain Axis Homeostasis in HFD‐fed Mice,” Ecotoxicology and Environmental Safety 306 (2025): 119307, 10.1016/j.ecoenv.2025.119307. [DOI] [PubMed] [Google Scholar]
- 22. Zhou X., Wu J., He Q., et al., “Short‐chain Chlorinated Paraffins Induce Liver Injury in Mice through Mitochondrial Disorders and Disruption of Cholesterol‐bile Acid Pathway,” Environmental Pollution 364 (2025): 125323, 10.1016/j.envpol.2024.125323. [DOI] [PubMed] [Google Scholar]
- 23. Zhang L., Zhang D., Xu B., et al., “Medium‐Chain Chlorinated Paraffins Altered Neurobehavior and Induced Neuroinflammation Associated with Disordered Intestinal Homeostasis,” Journal of Agricultural and Food Chemistry 73, no. 28 (2025): 17934–17943, 10.1021/acs.jafc.5c04398. [DOI] [PubMed] [Google Scholar]
- 24. Qi S., Dong S., Fan M., Xue X., Wu L., and Wang P., “Stress Response in the Honeybee (Apis mellifera L.) Gut Induced by Chlorinated Paraffins at Residue Levels Found in Bee Products,” Environmental Science & Technology 57, no. 31 (2023): 11442–11451, 10.1021/acs.est.3c01827. [DOI] [PubMed] [Google Scholar]
- 25. Borgstahl G. E. O., Parge H. E., Hickey M. J., Beyer W. F., Hallewell R. A., and Tainer J. A., “The Structure of human Mitochondrial Manganese Superoxide Dismutase Reveals a Novel Tetrameric Interface of Two 4‐helix Bundles,” Cell 71, no. 1 (1992): 107–118, 10.1016/0092-8674(92)90270-m. [DOI] [PubMed] [Google Scholar]
- 26. Bianchi A., Becuwe P., Franck P., and Dauca M., “Induction of MnSOD Gene by Arachidonic Acid Is Mediated by Reactive Oxygen Species and p38 MAPK Signaling Pathway in human HepG2 Hepatoma Cells,” Free Radical Biology and Medicine 32, no. 11 (2002): 1132–1142, 10.1016/s0891-5849(02)00834-1. [DOI] [PubMed] [Google Scholar]
- 27. Zhang Y., Wei G., Liu W., et al., “Nanozymes for nanohealthcare,” Nature Reviews Methods Primers 4, no. 1 (2024): 34, 10.1038/s43586-024-00315-5. [DOI] [Google Scholar]
- 28. Song G., Xu J., Zhong H., et al., “Single‐Atom Ce‐N4‐C‐(OH)2 Nanozyme‐Catalyzed Cascade Reaction to Alleviate Hyperglycemia,” Research 6 (2023): 0095, 10.34133/research.0095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Zhou Y., Liu C., Yu Y., et al., “An Organelle‐Specific Nanozyme for Diabetes Care in Genetically or Diet‐Induced Models,” Advanced Materials 32, no. 45 (2020): 2003708, 10.1002/adma.202003708. [DOI] [PubMed] [Google Scholar]
- 30. Wei H., Huang H., He H., et al., “Pt–Se Hybrid Nanozymes with Potent Catalytic Activities to Scavenge ROS/RONS and Regulate Macrophage Polarization for Osteoarthritis Therapy,” Research 7 (2024): 0310, 10.34133/research.0310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Lau H. C. H., Zhang X., and Yu J., “Gut Microbiome in Metabolic Dysfunction‐associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma,” Nature Reviews Gastroenterology & Hepatology 22, no. 9 (2025): 619–638, 10.1038/s41575-025-01089-1. [DOI] [PubMed] [Google Scholar]
- 32. Tilg H., Adolph T. E., and Trauner M., “Gut‐liver Axis: Pathophysiological Concepts and Clinical Implications,” Cell Metabolism 34, no. 11 (2022): 1700–1718, 10.1016/j.cmet.2022.09.017. [DOI] [PubMed] [Google Scholar]
- 33. Liu T., Ma Y., Zhang M., and Wei J., “Beyond Organ Boundaries: Molecular Mechanisms of Hepatic Encephalopathy and Parkinson's Disease from the Perspective of the Gut–Liver–Brain Axis,” Research 9 (2026): 1084, 10.34133/research.1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. You M., Zhou L., Wu F., Zhang L., Zhu S.‐X., and Zhang H.‐X., “Probiotics for the Treatment of Hyperlipidemia: Focus on Gut‐liver Axis and Lipid Metabolism,” Pharmacological Research 214 (2025): 107694, 10.1016/j.phrs.2025.107694. [DOI] [PubMed] [Google Scholar]
- 35. Kim G., Chen Z., Li J., et al., “Gut‐liver Axis Calibrates Intestinal Stem Cell Fitness,” Cell 187, no. 4 (2024): 914–930.e20, 10.1016/j.cell.2024.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Wang Y., Cheng N., Zhang Q., et al., “Longitudinal Multi‐Omics Analysis of the Gut‐Liver Axis: Unraveling the Molecular Mechanisms of Metabolic Homeostasis Regulation by Pd@Pt Nanozymes,” Materials Today Bio 32 (2025): 101685, 10.1016/j.mtbio.2025.101685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Kumar S., Adjei I. M., Brown S. B., Liseth O., and Sharma B., “Manganese Dioxide Nanoparticles Protect Cartilage from Inflammation‐induced Oxidative Stress,” Biomaterials 224 (2019): 119467, 10.1016/j.biomaterials.2019.119467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Zhu Y., Wang W., Cheng J., et al., “Stimuli‐Responsive Manganese Single‐Atom Nanozyme for Tumor Therapy via Integrated Cascade Reactions,” Angewandte Chemie International Edition 60, no. 17 (2021): 9480–9488, 10.1002/anie.202017152. [DOI] [PubMed] [Google Scholar]
- 39. Li L., Zhang J., Yan C., et al., “Manganese‐Based Polyoxometalate Nanozyme‐Metformin Co‐functionalized Hydrogel Promotes Diabetic Wound Regeneration by Enhancing Phagocyte Efferocytosis,” Research 8 (2025): 0964, 10.34133/research.0964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Ma X., He C., Wang Y., et al., “Mechanisms and Applications of Manganese‐Based Nanomaterials in Tumor Diagnosis and Therapy,” Biomaterials Research 29 (2025): 0158, 10.34133/bmr.0158. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Jin Y., “On the Origin of Life on Earth: the Nanozymes Hypothesis, and More,” Research 8 (2025): 1025, 10.34133/research.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Li W., Guo X., Geng P., et al., “Rational Design and General Synthesis of Multimetallic Metal–Organic Framework Nano‐Octahedra for Enhanced Li–S Battery,” Advanced Materials 33, no. 45 (2021): 2105163, 10.1002/adma.202105163. [DOI] [PubMed] [Google Scholar]
- 43. Chen B., Yang X., Zeng X., et al., “Multicomponent Metal Oxides Derived from Mn‐BTC Anchoring with Metal Acetylacetonate Complexes as Excellent Catalysts for VOCs and CO Oxidation,” Chemical Engineering Journal 397 (2020): 125424, 10.1016/j.cej.2020.125424. [DOI] [Google Scholar]
- 44. Reinsch H. and Stock N., “Formation and Characterisation of Mn‐MIL‐100,” Crystengcomm 15, no. 3 (2013): 544–550, 10.1039/c2ce26436f. [DOI] [Google Scholar]
- 45. Maiti S., Pramanik A., Dhawa T., Sreemany M., and Mahanty S., “Bi‐metal Organic Framework Derived Nickel Manganese Oxide Spinel for Lithium‐ion Battery Anode,” Materials Science and Engineering: B 229 (2018): 27–36, 10.1016/j.mseb.2017.12.018. [DOI] [Google Scholar]
- 46. Férey G., Serre C., Mellot‐Draznieks C., et al., “A Hybrid Solid with Giant Pores Prepared by a Combination of Targeted Chemistry, Simulation, and Powder Diffraction,” Angewandte Chemie International Edition 43, no. 46 (2004): 6296–6301, 10.1002/anie.200460592. [DOI] [PubMed] [Google Scholar]
- 47. Lin A., Liu Q., Zhang Y., et al., “A Dopamine‐Enabled Universal Assay for Catalase and Catalase‐Like Nanozymes,” Analytical Chemistry 94, no. 30 (2022): 10636–10642, 10.1021/acs.analchem.2c00804. [DOI] [PubMed] [Google Scholar]
- 48. Joorabloo A. and Liu T., “Recent Advances in Reactive Oxygen Species Scavenging Nanomaterials for Wound Healing,” Exploration 4, no. 3 (2024): 20230066, 10.1002/EXP.20230066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Zhang N., Zhang Z., Yan S., et al., “Bridge‐Oxygen Bond: an Active Group for Energy Electrocatalysis,” Advanced Functional Materials 35, no. 34 (2025): 2500351, 10.1002/adfm.202500351. [DOI] [Google Scholar]
- 50. Geng N., Luo Y., Cao R., et al., “Effect of Short‐chain Chlorinated Paraffins on Metabolic Profiling of Male SD Rats,” Science of the Total Environment 750 (2021): 141404, 10.1016/j.scitotenv.2020.141404. [DOI] [PubMed] [Google Scholar]
- 51. Mu Y.‐W., Yao W.‐H., Li H., et al., “Short‐chain Chlorinated Paraffins at Environmentally Relevant Doses Disrupt Glucose Homeostasis and Insulin Signaling by Macrophage‐Mediated Inflammation,” Journal of Hazardous Materials 495 (2025): 139144, 10.1016/j.jhazmat.2025.139144. [DOI] [PubMed] [Google Scholar]
- 52. Zhao X., Zhang T., Zheng Y., et al., “Gut Microbiota from Short‐Chain Chlorinated Paraffin‐Exposed Mice Promotes Astrocyte Activation by Disrupting the Intestinal Tight Junction via Zonulin Upregulation,” Journal of Agricultural and Food Chemistry 71, no. 21 (2023): 8192–8202, 10.1021/acs.jafc.3c01058. [DOI] [PubMed] [Google Scholar]
- 53. Belkessa S., Pasolli E., Medrouh B., et al., “Structure Analysis of human Gut Microbiota Associated with Single‐celled Gut Protists Using Next‐Generation Sequencing of 16S and 18S rRNA Genes,” Computational and Structural Biotechnology Journal 27 (2025): 2955–2967, 10.1016/j.csbj.2025.06.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Shu C., Zhang W., Zhang Y., et al., “Copper‐Bearing Metal‐Organic Framework with Mucus‐Penetrating Function for the Multi‐Effective Clearance of Mucosal Colonized Helicobacter pylori,” Research 7 (2024): 0358, 10.34133/research.0358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Scheppach W., “Effects of Short Chain Fatty Acids on Gut Morphology and Function,” Gut 35, no. 1 (1994): S35–S38, 10.1136/gut.35.1_suppl.s35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Santos A. A., Afonso M. B., Ramiro R. S., et al., “Host miRNA‐21 Promotes Liver Dysfunction by Targeting Small Intestinal Lactobacillus in Mice,” Gut Microbes 12, no. 1 (2020): 1840766, 10.1080/19490976.2020.1840766. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Horackova S., Plockova M., and Demnerova K., “Importance of Microbial Defence Systems to Bile Salts and Mechanisms of Serum Cholesterol Reduction,” Biotechnology Advances 36, no. 3 (2018): 682–690, 10.1016/j.biotechadv.2017.12.005. [DOI] [PubMed] [Google Scholar]
- 58. Ruiz L., Margolles A., and Sanchez B., “Bile Resistance Mechanisms in Lactobacillus and Bifidobacterium ,” Frontiers in Microbiology 4 (2013): 396, 10.3389/fmicb.2013.00396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Nie K., Ma K., Luo W., et al., “ Roseburia Intestinalis: a Beneficial Gut Organism from the Discoveries in Genus and Species,” Frontiers in Cellular and Infection Microbiology 11 (2021): 757718, 10.3389/fcimb.2021.757718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Douglas G. M., Maffei V. J., Zaneveld J. R., et al., “PICRUSt2 for Prediction of Metagenome Functions,” Nature Biotechnology 38, no. 6 (2020): 685–688, 10.1038/s41587-020-0548-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Liu C., Hu B., Cheng Y., Guo Y., Yao W., and Qian H., “In‐depth Analysis of the Mechanisms of Aloe Polysaccharides on Mitigating Subacute Colitis in Mice via Microbiota Informatics,” Carbohydrate Polymers 265 (2021): 118041, 10.1016/j.carbpol.2021.118041. [DOI] [PubMed] [Google Scholar]
- 62. Joseph S. B., Castrillo A., Laffitte B. A., Mangelsdorf D. J., and Tontonoz P., “Reciprocal Regulation of Inflammation and Lipid Metabolism by Liver X Receptors,” Nature Medicine 9, no. 2 (2003): 213–219, 10.1038/nm820. [DOI] [PubMed] [Google Scholar]
- 63. Mansouri A., Gattolliat C. H., and Asselah T., “Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases,” Gastroenterology 155, no. 3 (2018): 629–647, 10.1053/j.gastro.2018.06.083. [DOI] [PubMed] [Google Scholar]
- 64. Yan M., Zhao Y., Man S., Dai Y., Ma L., and Gao W., “Diosgenin as a Substitute for Cholesterol Alleviates NAFLD by Affecting CYP7A1 and NPC1L1‐related Pathway,” Phytomedicine 125 (2024): 155299, 10.1016/j.phymed.2023.155299. [DOI] [PubMed] [Google Scholar]
- 65. Rizzolo D., Kong B., Taylor R. E., et al., “Bile Acid Homeostasis in Female Mice Deficient in Cyp7a1 and Cyp27a1 ,” Acta Pharmaceutica Sinica B 11, no. 12 (2021): 3847–3856, 10.1016/j.apsb.2021.05.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Lu X.‐R., Tao Q., Qin Z., et al., “A Combined Transcriptomics and Proteomics Approach to Reveal the Mechanism of AEE Relieving Hyperlipidemia in ApoE‐/‐ mice,” Biomedicine & Pharmacotherapy 173 (2024): 116400, 10.1016/j.biopha.2024.116400. [DOI] [PubMed] [Google Scholar]
- 67. Tagaras N., Song H., Sahar S., Tong W., Mao Z., and Buerki‐Thurnherr T., “Safety Landscape of Therapeutic Nanozymes and Future Research Directions,” Advanced Science 11, no. 46 (2024): 2407816, 10.1002/advs.202407816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Nikkhoo E., Dinari M., Lutzenkirchen J., and Hosseini‐Monjezi B., “Biomimetic and Biocompatible MOFs for Medical Applications: Advances, Challenges, and Future Directions,” Advances in Colloid and Interface Science 354 (2026): 103898, 10.1016/j.cis.2026.103898. [DOI] [PubMed] [Google Scholar]
- 69. Yang J., Zhang R., Zhao H., et al., “Bioinspired Copper Single‐Atom Nanozyme as a Superoxide Dismutase‐like Antioxidant for Sepsis Treatment,” Exploration 2, no. 4 (2022): 20210267, 10.1002/EXP.20210267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Yang L., Liu Y., Cui Z., Zhang Y., Zhang J., and Lian K., “Metabolomic Mechanisms of Short Chain Chlorinated Paraffins Toxicity in Rats,” Environmental Research 197 (2021): 111060, 10.1016/j.envres.2021.111060. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supporting File: advs78792‐sup‐0001‐SuppMat.docx.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
